Oxford Biomedica Receives GBP2.2 Million Grant For OXB-102 Compound
30th Apr 2014 14:16
LONDON (Alliance News) - Oxford Biomedica said Wednesday it had received a GBP2.2 million grant from the UK government's Technology Strategy Board to help fund a Phase I/II clinical trial of its compound OXB-102 in the treatment of Parkinson's. The compound is delivered with Oxford's LentiV Read More